December 4, 2007 – The Impella 2.5, a catheter-based heart pump device, supports high-risk patient’s weakened heart in the Abiomed PROTECT I trial conducted at the Texas Heart Institute at St. Luke’s Episcopal Hospital.
Texas Heart Institute at St. Luke’s Episcopal Hospital was one of the few facilities chosen to participate in the Abiomed PROTECT I trial for the Impella 2.5, the first FDA-approved trial for prophylactic, or preventative, use of a device during high-risk percutaneous coronary intervention (PCI) procedures.
